Stevenage, UK, December 10 2012 – Stevenage Bioscience Catalyst (SBC), the UK’s first open innovation bioscience campus, has appointed Dr Barbara Domayne-Hayman as its first entrepreneur-in-residence. Dr Domayne-Hayman will work with SBC and its tenants on strategy, as well as new business creation, with an initial focus on cell therapy and neuroscience. She is also a member of the recently established SBC Experts Panel.
Dr Domayne-Hayman is a company builder and deal-maker, who has successfully transitioned from working in large organisations to an entrepreneurial environment. During her time as CEO of Stabilitech Ltd and Commercial Director of Arrow Therapeutics Ltd, she was responsible for multiple agreements, developing teams and bringing in funding. Prior to Arrow, Dr Domayne-Hayman held business positions at Celltech and Zeneca, and consulted for Ernst & Young Strategy Group. She holds a Sloan Fellowship from London Business School, and has a BA and D.Phil in chemistry from the University of Oxford.
The SBC Experts Panel, convened to advise both the incubator and its tenants, comprises over 20 leading professionals active in the biosciences sector. Ranging from chemists and drug development experts to funders, lawyers and finance experts, its members are already actively engaged with the SBC community.
'We are delighted to have appointed Barbara, with her ideal skill set, as our first entrepreneur-in-residence,' said Dr Martino Picardo, CEO of Stevenage Bioscience Catalyst. 'This is an important role in a bioincubator and we look forward to working with her on new opportunities in the biotech and medtech areas. The Experts Panel has made a great start as well, and we will be adding new members as the need arises.'
SBC's Entrepreneur-in-Residence, Dr Barbara Domayne-Hayman, added, 'I've been impressed right from the start by the innovative and dynamic culture Martino and the team have built at SBC, and this is a great opportunity for me to work with them on emerging projects. In common with many people in biotech, one of my aims is to make a real contribution to society through the commercialisation of new science from industry and academia, and SBC is the ideal place to do that.'View Press Release